Investigational drug · Phase 3
TTP399
Also called: Cadisegliatin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 1 Diabetes (T1D), Diabetes Mellitus, Type 1.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "TTP399"
First trial start
2024
Jun 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TTP399", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 1 Diabetes (T1D)
- Diabetes Mellitus, Type 1
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TTP399" as an intervention, largest first.
- A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 DiabetesPivotal-lookingCompleted
vTv TherapeuticsIndustry
NCT01474083 · 248 participants · Start Nov 2011 · Primary completion Aug 2012
Drug: GK1-399 (formerly TTP399); GK1-399 (formerly TTP399) and 2 more · For: Type 2 Diabetes Mellitus
Sites: Little Rock, Arkansas; Chula Vista, California; DeLand, Florida · 11 sites in all
- Add Glucokinase Activator to Target A1cPivotal-lookingCompleted
vTv TherapeuticsIndustry
NCT02405260 · 190 participants · Start Mar 2015 · Primary completion Jul 2016
Drug: TTP399 400 mg; TTP399 800 mg and 2 more · For: Diabetes Mellitus, Type 2
Sites: Mesa, Arizona; Tuscon, Arizona; Canoga Park, California · 20 sites in all
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesPivotal-lookingActive, not recruiting
vTv TherapeuticsIndustry
NCT06334133 · 150 participants (planned) · Start Jun 14, 2024 · Primary completion Apr 2027
Drug: Cadisegliatin 800 mg QD; Cadisegliatin 800 mg BID and 1 more · For: Diabetes Mellitus, Type 1
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Concord, California · 48 sites in all
- Evaluation of TTP399 in Patients With Type 1 DiabetesPivotal-lookingCompleted
vTv TherapeuticsIndustry
NCT03335371 · 115 participants · Start Oct 25, 2017 · Primary completion Dec 20, 2019
Drug: TTP399; TTP399 and 1 more · For: Diabetes Mellitus, Type 1
Sites: Beverly Hills, California; Escondido, California; Aurora, Colorado · 15 sites in all
vTv TherapeuticsIndustry
NCT07616206 · 40 participants (planned) · Start Sep 29, 2026 · Primary completion Jun 2027
Drug: Cadisegliatin 800 mg QD; Placebo · For: Type 1 Diabetes (T1D)
Sites: Modesto, California; San Diego, California; Aurora, Colorado · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Impact of glucokinase activators on the gut microbiota of high-fat diet-induced obese and type 2 diabetic mice.
Gao L, Shao Q, Zhuo X, et al. · Front Microbiol 2026
- Identification of small molecule glucokinase activators for the treatment of diabetes based on plants from the traditional Chinese medicine: In silico analysis.
Khamlich J, Douiyeh I, Saih A, et al. · Microb Pathog 2024
- New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.
Haddad D, Dsouza VS, Al-Mulla F, et al. · Int J Mol Sci 2024
- Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.
Klein KR, Boeder SC, Freeman JLR, et al. · Diabetes Obes Metab 2022
- Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators.
Sharma P, Singh S, Sharma N, et al. · J Diabetes Metab Disord 2022
- A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes.
Thilagavathi R, Hosseini-Zare MS, Malini M, et al. · Chem Biol Drug Des 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.